Dexedrine dopes Paladin’s results

Paladin (Tor., PLB, $ 11.49) should surpass the $ 100 million (M $) in revenue in 2009 through the acquisition of exclusive marketing rights in Canada’s Dexedrine, a drug from GlaxoSmithKline. 

Read this French article on Les Affaires…

Picture of Claret

Claret

Author

  • Claret
    Claret Asset Management specializes in offering portfolio management services to high net worth clients. We are completely independent and free of conflicts of interest. Claret was founded in 1996 with the objective of answering the growing needs of private investors.

You may also enjoy:

Your wealth matters.

Sign up to our Newsletter for updates on when we publish new insights.

Linkedin Twitter Youtube